Christopher Anzalone - Mar 13, 2025 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Chief Executive Officer, Director
Signature
/s/Christopher Anzalone
Stock symbol
ARWR
Transactions as of
Mar 13, 2025
Transactions value $
-$774,975
Form type
4
Date filed
3/17/2025, 05:45 PM
Previous filing
Mar 5, 2025
Next filing
Apr 11, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Award $0 +340K +9.01% $0.00 4.11M Mar 13, 2025 Direct F1
transaction ARWR Common Stock Sale -$775K -51.4K -1.25% $15.07 4.06M Mar 13, 2025 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents performance awards granted on December 22, 2023, and certified on March 12, 2025, upon the achievement of certain performance goals.
F2 Partial disposition of shares to satisfy tax withholding obligations.
F3 The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $14.83 to $15.76, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F4 Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.